Eli Lilly and Company (LLY) Latest Stock News & Headlines
WEBGet the latest Eli Lilly and Company (LLY) stock news and headlines to help you in your trading and investing decisions.
Weight-loss drug drives Eli Lilly to raise 2024 sales forecast by $2 ...
WEBApr 30, 2024 · Eli Lilly and Danish rival Novo Nordisk are racing to increase production in a weight-loss market estimated to reach at least $100 billion by decade's end.
Lilly expands manufacturing footprint in Ireland with $1.8 billion ...
WEBINDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease.
Eli Lilly and Company (LLY) Latest Press Releases & Corporate News …
WEBGet the latest Eli Lilly and Company (LLY) stock news and headlines to help you in your trading and investing decisions.
All News - Eli Lilly and Company
WEBLilly's latest press releases, stories, news resources and more.
Lilly.com | Eli Lilly and Company
WEBINDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's …
News Release - Eli Lilly and Company
WEBFDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. May 13, 2022. PDF Version. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
Lilly hits record high after Mounjaro fuels forecast raise, rival data
WEBAug 8, 2023 · Eli Lilly on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares soaring 18% to a record...
News Release - Eli Lilly and Company
WEBINDIANAPOLIS, Aug. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg or 15 mg) in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.
Lilly drug slows Alzheimer's by 35%, bolstering treatment approach
WEBMay 3, 2023 · An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest...
Skip to content